Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial

Raphael J. Landovitz, Craig W. Hendrix, Mina C. Hosseinipour et al.|The Lancet HIV|2020

Cited by 171